Given MUC16 as a precedent for the clinical implementation of a mucin biomarker and growing evidence for mucin detection and association with outcomes in glioma, a careful evaluation of mucins as potential non-invasive precision biomarkers in GBM is indicated to help direct and interpret findings in this space. The gene discussed is MUC16; the disease is central nervous system cancer.